As acute myeloid leukemia (AML) xenograft models improve, the potential for using them to
evaluate novel therapeutic strategies becomes more appealing. Currently, there is little …

Relevant preclinical mouse models are crucial to screen new therapeutic agents for acute
myeloid leukemia (AML). Current in vivo models based on the use of patient samples are not …

Acute myeloid leukemia (AML) is a clonal disorder defined by the accumulation of
abnormally differentiated myeloid cells that are not mature; any myeloid lineage can be …

Most cases of human acute myeloid leukemia (AML) engraft in irradiated non-obese
diabetic/severe combined immunodeficient (NOD/SCID) mice. Intravenous transfer of as few …

In vitro studies of cultured native acute myelogenous leukemia (AML) blasts and cell lines
have contributed significantly to our present knowledge about the pathogenesis of AML. In …

From the early inception of the transplant models through to contemporary genetic and
xenograft models, evolution of murine leukaemic model systems have been critical to our …

Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with
poor outcome. Adequate model systems are required for preclinical studies to improve …

Over the past decade, xenografting human leukemia cells into mice with different levels of
immunodeficiency, with or without preconditioning, has provided an important tool to study …

Primary human AML cells can be isolated and studied in vitro, but many experimental
questions can only be addressed using in vivo models. In particular, tractable animal models …

Continuous xenografts from 10 children with acute lymphoblastic leukemia (ALL) were
established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice …